Iron deficiency without anaemia: a diagnosis that matters

Authors: Abdulrahman Al-Naseem, Abdelrahman Sallam, Shamim Choudhury and Jecko Thachil

Iron deficiency anaemia (IDA) currently affects 1.2 billion people and iron deficiency without anaemia (IDWA) is at least twice as common. IDWA is poorly recognised by clinicians despite its high prevalence, probably because of suboptimal screening recommendations. The World Health Organization (WHO) has set these at 130 g/L in non-pregnant females and 110 g/L in pregnant females. Nevertheless, symptoms of anaemia such as fatigue can be present without anaemic haemoglobin levels. Recognising IDWA as a clinical diagnosis is crucial to ensuring adequate management, especially for patients with chronic conditions such as heart failure (HF) where IDWA can increase long-term mortality.

Diagnostic definition of iron deficiency

Ferritin is an indicator of iron stores and is the most sensitive and specific biomarker for assessing ID. The WHO defines low ferritin as levels <15 µg/L for adults and <12 µg/L for children. However, in clinical practice, when ferritin levels dip below 30 µg/L, ID can be ascertained. Ferritin is an acute-phase reactant that is increased in serum during chronic inflammation. Cut-off values for ferritin in ID are increased to 100 µg/L in states of chronic inflammation. Transferrin saturation (TSAT) levels below 20% are also diagnostic of ID. In chronic inflammatory conditions when ferritin levels are 100–300 µg/L, TSAT should be used to diagnose ID. Serum iron levels fluctuate throughout the day and should not be used for diagnosis. Ferritin levels are not widely used. Although hepcidin is usually low or normal in IDWA, it helps distinguish AID from functional ID (FID). The sTFR is a valuable indicator of ID as, unlike ferritin, it is unaffected by inflammation. Unfortunately, performing this test takes too long and it is not widely available. When haemoglobin levels are normal, a low RHC indicates early ID in functional stores and hints at iron need, pre-anaemia and a risk of developing IDA.

The distinction between IDA and IDWA relies on the use of strict haemoglobin cut-offs. However, clinicians should consider the fact that normal haemoglobin ranges have been set using population data. Essentially, what may be a normal haemoglobin level for one person may be abnormal for another, especially if a patient has a haemoglobin level in the low normal range but their usual haemoglobin levels are higher. Patients suffering from ID should be treated regardless of whether they are explicitly defined as anaemic. Cut-off haemoglobin ranges are useful, but their limitations should be kept in mind and patients should be assessed on a case-by-case basis.

Causes of iron deficiency

Iron has both a storage pool and a functional pool. The storage pool is the reticuloendothelial system which consists of the liver,
spleen and lymph nodes. The functional pool consists of red blood cells, bone marrow and cardiac and skeletal muscle. Iron is absorbed in the duodenum via specific transporters and is carried by transferrin molecules to the storage and functional pools. Iron deficiency can be absolute or functional. AID is when the storage pool is iron-deficient due to reduced intake, increased needs, reduced absorption or excessive loss. AID also causes low iron levels within the functional pool. In FID the burden is the chronic inflammation, causing cytokine and hepcidin release. Hepcidin causes iron deficiency via the blockage of an iron exporter known as ferroportin. There are two ways in which this blockage causes ID. First, it reduces iron absorption in the duodenum; second, it causes iron retention within the storage pools. This means that despite normal iron levels within the storage pools, functional pools are iron deficient and cannot utilise the stored iron for vital body processes.

Causes of iron deficiency can be grouped into the following categories: inadequate dietary intake, increased body needs, reduced absorption, chronic inflammation and chronic blood loss. Inadequate intake can result from iron-deficient diets, such as the increasingly popular vegan diets, or having higher iron requirements, as seen in growing children and pregnant women. Athletes and those performing in demanding sports have greater iron losses through urine and sweat during vigorous activity. Iron absorption occurs mainly in the proximal small intestine. The presence of sufficient gastric acid is required for the reduction of $\text{Fe}^{3+}$ to $\text{Fe}^{2+}$, which is more readily absorbed. Bariatric surgery patients are highly susceptible to ID due to a decreased absorptive surface area and/or reduced gastric acid secretion. A lower postoperative intake of dietary iron further increases the risk of ID. Less commonly, *Helicobacter pylori* infection may cause ID due to reduced iron absorption and blood loss. Patients with autoimmune gastritis also incur a loss of gastric acid secretion, thus failing to absorb iron effectively. Moreover, chronic use of proton pump inhibitors or histamine-2 receptor antagonists can increase the risk of ID via a similar mechanism. The consumption of coffee, tea or calcium (in supplements or dairy products) has been reported to reduce iron absorption. The significance of these dietary components as causes of ID is sometimes overlooked. Chronic inflammation, such as in coeliac disease, inflammatory bowel disease (IBD) and HF, increases hepcidin production, blocking iron transporters and reducing absorption, and causes iron entrapment within storage pools. This ultimately results in FID. ID may also result from major or chronic occult blood losses. This is common in women with menstruation, and is further amplified in obesity and during rapid growth in adolescence, which may deplete iron stores. Other causes include nosebleeds, GI bleeds (eg...
angiodysplasia), surgical procedures, injuries, accidents, and the use of intrauterine devices, anticoagulants or antiplatelets.\textsuperscript{2,12,13,23-25}

Fig 2 summarises the causes of ID and provides a clinically relevant background of the pathophysiology at play.

**Clinical features**

It is well established that iron plays an indispensable role in haemoglobin and myoglobin synthesis. Less appreciated, however, is its role in mitochondrial functioning, including the synthesis of cofactors and enzymes necessary for cellular respiration.\textsuperscript{26,27} Consequently, highly metabolic cells such as cardiomyocytes and skeletal muscle cells are dependent on iron for optimum functioning.\textsuperscript{10} A randomised controlled trial (RCT) by Melenovsky et al showed that ID reduces aerobic respiration and citric acid cycle enzyme activity in advanced HF.\textsuperscript{28} Similarly, several studies have demonstrated the negative impact of ID on cellular metabolism.\textsuperscript{28-31} A recent RCT of 40 chronic HF patients with ID demonstrated enhanced skeletal muscle energetics following iron supplementation.\textsuperscript{31} Although many cellular processes depend on iron, it is likely that they are only impacted in severe ID, where anaemia would likely be present. More research is needed to further clarify the effects of IDWA on cellular processes and how such effects would relate to the clinical presentation.

Symptoms of ID such as fatigue and exercise intolerance are nonspecific, making it difficult to identify whether ID is the culprit or a chronic disease such as HF, which may present with similar symptoms.\textsuperscript{32} Other causes such as hypothyroidism, depression and burnout may also be responsible. Additionally, it is difficult to distinguish IDWA from IDA based solely on symptoms given their overlap; the main clinical difference is that symptoms are more severe in IDA. A recent systematic review concluded that iron supplementation in IDWA improves subjective measures of fatigue.\textsuperscript{4} In IDWA patients with coexisting HF or IBD, intravenous (IV) supplementation improves symptom control and quality of life, respectively.\textsuperscript{32,33} However, evidence on the effect of iron supplementation on physical activity, often assessed by maximal oxygen consumption tests (VO$_2$ max), is mixed.\textsuperscript{15,34} Severe ID may also cause cardiac and skeletal myopathy, which is detrimental in HF.\textsuperscript{35} This is due to impaired clearance of reactive oxygen species, increasing oxidative stress and thereby weakening cardiac muscle. Ultimately, the atrophy of cardiac, peripheral, and respiratory muscles leads to reduced exercise tolerance and dyspnoea on exertion.\textsuperscript{36} In HF, mitochondrial function is already impaired, and the superimposed effect of ID can be deleterious.\textsuperscript{37} The clinical features of IDWA are summarised in Fig 3.

**Iron deficiency in pregnancy**

IDA increases maternal morbidity and the risk of poor pregnancy outcomes, including intrauterine growth restriction, prematurity and low birth weight.\textsuperscript{38} Compared to non-iron-deficient women, gravidas with depleted iron stores or IDWA at the start of pregnancy are more likely to develop pre- and postnatal ID and have a newborn with a lower birth weight.\textsuperscript{39} Anaemia is a late manifestation of ID. During foetal growth and when iron is scarce,
A recent RCT of 252 IDWA patients found that providing a short term combination therapy of IV iron, erythropoietin alpha, vitamin B12 and folic acid reduced blood transfusions in patients with preoperative IDWA undergoing elective cardiac surgery. Furthermore, preoperative supplementation of non-anaemic patients undergoing orthopaedic surgery with oral iron, vitamin C, and folic acid reduced blood transfusions. The British Committee for Standards in Haematology recommends iron supplementation in patients with IDWA (ferritin <100 µg/L and TSAT <20%) who are planned to undergo surgery with a predicted haemoglobin loss of >30 g/L.

An international consensus statement on perioperative ID and anaemia emphasised the importance of screening for and managing IDWA prior to surgery. Elective surgery with significant expected blood loss should be postponed until ID and/or anaemia is corrected to reduce the risk of postoperative anaemia. The recommendation is that oral iron is used when surgery is more than 6 weeks away; otherwise intravenous supplementation is best. Collaboration between primary and secondary care practitioners is vital to effective management of preoperative IDWA. Ideally, testing should occur in primary care when a referral is first made to avoid delays to surgery.

In the future, raising awareness of IDWA among clinicians, especially in primary care, could reduce the prevalence of undiagnosed IDWA. This would minimise the risk of preoperative IDWA and IDA and improve patient blood management.

**Directions for management**

IDWA should be treated when identified, with a target ferritin of 100 mg/L. Treatment should be continued until ferritin levels have normalised and symptoms have resolved. Patients should be offered dietary advice and oral iron replacement. IV replacement should be considered for symptomatic patients with treatment-resistant IDWA. Furthermore, ferritin levels should be checked every 6–12 months following treatment, especially in heavily menstruating women and those considering pregnancy.

Diet is important in the management of IDWA. Patients should aim to consume meat, poultry, or fish at least five times a week, with complementary wholemeals, legumes, and vegetables. They may also be referred to a dietitian for detailed assessment and advice. Nevertheless, dietary supplementation alone may not be enough to correct the deficiency, thus necessitating medicinal replacement.

Oral iron is associated with gastrointestinal side effects such as constipation, diarrhoea, dyspepsia, and nausea, which have been associated with poor adherence. Using single doses on alternate days as opposed to multiple doses on consecutive days has been shown to result in higher absorption and better regulation of hepcidin levels in iron-depleted women. The recommended oral dose is 28–50 mg iron daily or 100 mg on alternate days for 25 days. Ideally, patients should be contacted 1 week following the start of treatment to assess drug tolerance, with changes to formulation or dose agreed if necessary. Oral iron supplementation is inadequate, patients should be considered for IV replacement and referral to a specialist. Once ferritin levels have corrected, patients should be followed up with blood tests every 6–12 months, with replacement reintroduced if necessary.

Where oral iron is ineffective or poorly tolerated, patients should be offered IV supplementation. It should also be used in IDWA.
to circumvent diminished absorption following gastric bypass, in IBD where the intestinal mucosa is damaged, and also in other chronic inflammatory conditions, including HF, where hepcidin is elevated.\(^{53-55}\) IV iron has proven to be effective and well-tolerated in IDWA, and may be more efficacious than oral preparations.\(^{52,56}\)

Around 1% of patients experience minor infusion reactions, which should prompt cessation of infusion and management of symptoms (see Gómez-Ramírez et al for detailed guidance).\(^{57}\) Severe reactions have traditionally been overstated due to the risks associated with high molecular weight iron dextran (HMWID), which has now been replaced by substantially safer formulations.\(^{58-60}\) In the UK, these are low molecular weight dextran, iron sucrose, ferric carboxymaltose and iron isomaltoside (known in the US as ferric derisomaltose).\(^{61}\) Ferumoxytol, which was withdrawn from European markets in 2015, continues to be available in the USA, and has been shown to be just as safe.\(^{58,62}\) Excluding HMWID, the risk of severe reactions is very low (1,250,000 administrations).\(^{57,63}\) Nevertheless, it is essential to administer IV iron in a setting where such adverse effects can be adequately managed.\(^3\) As with oral iron, follow up is essential.\(^{44}\) The suggested management pathway for IDWA is summarised in Fig 4.

**Conclusion**

Despite the simplicity of pathogenesis and treatment, IDWA often falls outside the scope of clinical suspicion. It is important to not only spread awareness about the condition in the medical community, but to also develop guidelines and pathways to assist clinicians. Doing so requires greater collaboration between specialists and general practitioners to identify and treat IDWA, especially preoperatively and in the context of pregnancy. In this paper, we have attempted to develop a concise guide for clinicians. Nonetheless, further research is needed to identify the best diagnostic serum markers, treatment targets, and optimal oral iron dosing regimens for IDWA.

**Key points**

- Within the body, iron has roles other than haemoglobin synthesis.
- Iron deficiency (ID) and anaemia are not synonymous; patients with ID can present with symptoms without having anaemia. Therefore iron deficiency without anaemia (IDWA) must be recognised as a clinical diagnosis on its own.
- Haemoglobin ranges are based on averages and should not be used as strict cut-offs. Haemoglobin levels in the low normal range may not be normal for some people as they may be accustomed to higher levels.
- Diagnosis currently depends on haemoglobin levels, ferritin levels and transferrin saturation. However, further research into the use of newer biomarkers is needed.
- Many causes of ID are overlooked and clinicians need to maintain high clinical suspicion.
- Females with IDWA must be treated before the start of their pregnancy to avoid the risks of perinatal and postnatal ID.

© Royal College of Physicians 2021. All rights reserved.
or IDA. These include permanent neurocognitive effects on children and having a child with a low birth weight.

ID with or without anaemia should be ruled out in the preoperative setting as failure to do so may have a negative effect on patient outcomes.

Preoperative IDWA must be studied in more depth, as the literature on this topic is sparse. There is a need for more universal pre-operative screening and treatment.

IDWA should be treated when identified. Specific guidelines on whom to treat and how to treat must be developed.

Oral iron is the first line treatment for IDWA.

Newer formulations of IV iron are much safer than traditionally thought, and should be used where oral iron is poorly tolerated or ineffective.

Conflicts of interest

Jecko Thachil has received honoraria from Norgine pharmaceuticals.

References


51 Stoffel NU, Cercamondi CI, Brittenham G et al. Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials. *Lancet Haematol* 2017;4:e524–33.


Address for correspondence: Mr A Al-Naseem, School of Medicine, Faculty of Biology, Medicine and Health, University of Manchester, Oxford Road, Manchester M13 9PL, UK. Email: abdulrahman.alnaseem@student.manchester.ac.uk